31 completed, 4 not yet recruiting, 4 recruiting, 3 withdrawn. 13 Phase 4, 12 Phase 2, 8 Phase 1, 8 Phase 3, 6 Not applicable.
Follow Racivir: new trials by email Literature Review of Racivir trials Research Report on Racivir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study on Retention in Care and on Clinical Chracteristics of HIV-infected Women Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIKWO). Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF) - HIV 1 Infection | Not yet recruiting | Ente Ospedaliero Ospedali Galliera | 100 | 2026-12-15 | 2026-10-09 | |
| An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC) - HIV Infection | Phase 3 | Not yet recruiting | University College, London | 800 | 2026-11-01 | 2026-08-28 |
| Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIV Switch from an ART regimen containing lamivudine (3TC) or emtricitabine (FTC) + tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) to DOR/ISL, Switch from an nucleoside reverse transcriptase inhibitor (NRTI)-sparing ART regimen containing greater than or equal to 2 drugs to DOR/ISL, Continue SoC ART - Epigenetic Aging | Phase 2 | Not yet recruiting | The University of Texas Health Science Center, Houston | 60 | 2026-10-30 | 2026-10-23 |
| A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC) - HIV Infections | Phase 2 | Recruiting | ViiV Healthcare | 186 | 2026-02-11 | 2026-07-23 |
| Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers tenofovir alafenamide [TAF] 50 mg/emtricitabine [FTC] 400mg - Healthy Volunteer, HIV Prevention | Phase 1 | Recruiting | Johns Hopkins University | 24 | 2026-01-06 | 2026-02-13 |
| Safety Of Nrtis for Alzheimer's Therapeutic Advancement in Singapore Study Emtricitabine (FTC), Descovy® (TAF/FTC), Placebo to Match Emtricitabine 200mg/Tenofovir Alafenamide 25 mg. - Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD) | Phase 1 | Active not recruiting | National University Hospital, Singapore | 48 | 2025-06-30 | 2026-08-10 |
| Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience DTG/3TC, Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF) - HIV Infection, Metabolic Syndrome | Phase 4 | Recruiting | Instituto Mexicano del Seguro Social | 124 | 2025-04-01 | 2025-06-26 |
| Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI, Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR) - HIV Infections, HBV Coinfection | Phase 2 | Not yet recruiting | ANRS, Emerging Infectious Diseases | 140 | 2025-02-01 | 2025-02-05 |
| Rehabilitation Exercise With MObile Technology and Education After Acute Coronary Syndrome Telerehabilitation (Tele RCV), Rehabilitation (RCV) - Acute Coronary Syndrome | Not applicable | Withdrawn | University Hospital, Toulouse | 2024-12-01 | 2026-06-30 | |
| UNCPM 22314 - Pregnancy, Infant and Maternal Health Outcomes Study Initiating daily oral PrEP during pregnancy, Already using daily oral PrEP at the time of pregnancy diagnosis, Initiating injectable PrEP during pregnancy - Pre-exposure Prophylaxis, HIV Prevention | Phase 4 | Recruiting | University of North Carolina, Chapel Hill | 621 | 2024-04-17 | 2026-05-05 |
| Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day, Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day, Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine. - HIV Infections, Fatty Liver Disease | Phase 4 | Completed | Fundacion SEIMC-GESIDA | 63 | 2023-05-26 | 2025-07-18 |
| Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South Africa Tenofovir disoproxil fumarate + lamivudine/emtricitabine (TDF+3TC /FTC) - HIV Infection | Phase 4 | Active not recruiting | Professor Francois Venter | 1900 | 2023-05-19 | 2025-06-05 |
| The Women TAF-FTC Benchmark Study co-formulated 25mg TAF/ 200mg FTC - HIV Infections | Phase 2 / Phase 3 | Completed | University of Washington | 54 | 2023-04-10 | 2026-06-18 |
| The Women TDF-FTC Benchmark Study co-formulated 300 mg TDF/ 200mg FTC - HIV Infections | Phase 2 | Completed | University of Washington | 72 | 2022-04-25 | 2026-06-15 |
| Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide Doravirine 100 Mg, Integrase strand transfer inhibitors, Tenofovir alafenamide/emtricitabine - HIV Infections | Phase 4 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 147 | 2021-07-27 | 2025-07-02 |
| A Study of JNJ-56136379 in Healthy Participants JNJ-56136379, Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF) - Healthy | Phase 1 | Withdrawn | Janssen Research & Development, LLC | 2021-05-06 | 2021-07-15 | |
| Body Composition Sub-study of the D2EFT Trial Darunavir (DRV) 800 milligram (MG) Oral Tablet, Ritonavir 100 MG Oral Tablet, N(t)RTIs - HIV Infections | Phase 4 | Completed | Kirby Institute | 155 | 2019-12-05 | 2025-01-09 |
| HIV Pre-exposure Prophylaxis Implementation Study in South Korea tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration - HIV Infections | Not applicable | Unknown | Yonsei University | 200 | 2018-08-28 | 2020-10-12 |
| Same-Day Treatment With Genvoya vs. EFV/TDF/3TC Elvitegravir, Cobicistat, TAF, FTC, Efavirenz, TDF, and 3TC - HIV/AIDS | Not applicable | Withdrawn | Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic | 2018-05-01 | 2020-03-18 | |
| A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC - HIV-1 | Phase 3 | Completed | Janssen Scientific Affairs, LLC | 109 | 2017-07-31 | 2025-02-04 |
Showing 20 of 46. Sign in to see all of them.
HIV Infections (29) · Acquired Immunodeficiency Syndrome (6) · Acute Coronary Syndrome (1) · Alzheimer Disease (1) · Breast Feeding (1) · Cognitive Dysfunction (1) · Hepatitis B (1) · Metabolic Syndrome (1) · Non-alcoholic Fatty Liver Disease (1)
National Institute of Allergy and Infectious Diseases (NIAID) (4) · ANRS, Emerging Infectious Diseases (3) · Gilead Sciences (3) · French National Agency for Research on AIDS and Viral Hepatitis (2) · Janssen Scientific Affairs, LLC (2) · Pharmasset (2) · University of North Carolina, Chapel Hill (2) · University of Washington (2) · A.O. Ospedale Papa Giovanni XXIII (1) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · CONRAD (1) · Calmy Alexandra (1) · Centers for Disease Control and Prevention (1) · Ente Ospedaliero Ospedali Galliera (1) · Fundacion SEIMC-GESIDA (1)
United States (21) · Puerto Rico (4) · Argentina (3) · France (3) · South Africa (3) · Italy (2) · Kenya (2) · Mexico (2) · South Korea (2) · Spain (2) · Thailand (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Brazil (1)
Genevieve Chene, MD, PhD (2) · Jean-Michel Molina, MD, PhD (2) · Kenneth K Mugwanya, MBChB, MS, PhD (2) · Peter L Anderson, PharmD (2) · Ross E. McKinney, Jr., MD (2) · Albert Liu, MD, MPH (1) · Allison L. Agwu, MD, Sc.M. (1) · Andrew Cheng, MD, PhD (1) · Andrew Zolopa, MD (1) · Ann J. Melvin, MD (1) · Anne F Luetkemeyer, MD (1) · Cham Herath (1) · Charles E Davis, MD (1) · Christopher Chen (1)
PMID 15717256, PMID 16421366, PMID 17591032, PMID 18981766, PMID 18987623, PMID 19104016, PMID 19307941, PMID 19357529, PMID 19906624, PMID 20156091, PMID 21036772, PMID 21288774, PMID 25763783, PMID 27353267, PMID 27572401, PMID 28604824, PMID 31879782, PMID 33170863, PMID 33999786, PMID 38754068, PMID 38860025, PMID 39334032, PMID 40924774, PMID 41847923, PMID 42098649
2025 (1), DP1DA060602 (1), P01HD112215 (1), R01AI155086 (1), U01AI068632 (1), UM1AI068636 (1)